Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24866019 | 1.00 | TNK2 (0.30) | TNK2 | |
| SCHEMBL23685890 | 0.86 | TNK2 (0.31) | TNK2 | |
| SCHEMBL23822912 | 0.82 | TNK2 (0.35) | TNK2 | |
| SCHEMBL24512501 | 0.81 | POLRMT (0.32) | — | |
| SCHEMBL20144211 | 0.80 | TMPRSS2 (0.44) | TNK2 | |
| SCHEMBL25608337 | 0.80 | MGLL (0.38) | TNK2 | |
| SCHEMBL24789794 | 0.79 | PIK3CD (0.34) | — | |
| SCHEMBL24149284 | 0.79 | — | — | |
| SCHEMBL18666907 | 0.78 | TMPRSS2 (0.36) | TNK2 | |
| SCHEMBL4970753 | 0.78 | TMPRSS2 (0.36) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022082093-A1 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | Neonc Technologies, Inc. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210369619-A1 | TRANSMUCOSAL PHARMACEUTICAL COMPOSITIONS OF ANTIVIRAL DRUGS | Jubilant Generics Limited (IN) | 2021-12-02 | — | — | US | disclosed |
| US-11020349-B1 | Transmucosal dosage forms of remdesivir | Jubilant Generics Limited | 2021-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | TNK2 1941/4885 |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | TNK2 1941/4885 |
| US-20210369619-A1 | TRANSMUCOSAL PHARMACEUTICAL COMPOSITIONS OF ANTIVIRAL DRUGS | CYP3A4, UGT1A4, CYP3A5 | TNK2 4192/4885 |
| US-11020349-B1 | Transmucosal dosage forms of remdesivir | CYP3A5, CYP2D6, CYP3A4 | TNK2 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.